The fosfomycin resistance enzymes, FosB, from Grampositive organisms, are M 2+ -dependent thiol tranferases that catalyze nucleophilic addition of either L-cysteine (L-Cys) or bacillithiol (BSH) to the antibiotic, resulting in a modified compound with no bacteriacidal properties. Here we report the structural and functional characterization of FosB from Bacillus cereus (FosB , indicate that the antibiotic coordinates to the active site metal center in an orientation similar to that found in the structurally homologous manganese-dependent fosfomycin resistance enzyme, FosA. Surface analysis of the FosB Bc structures show a well-defined binding pocket and an access channel to C1 of fosfomycin, the carbon to which nucleophilic addition of the thiol occurs. The pocket and access channel are appropriate in size and shape to accommodate L-Cys or BSH. Further investigation of the structures revealed that the fosfomycin molecule, anchored by the metal, is surrounded by a cage of amino acids that hold the antibiotic in an orientation such that C1 is centered at the end of the solvent channel, positioning the compound for direct nucleophilic attack by the thiol substrate. In addition, the structures of FosB Bc in complex with the L-Cys-fosfomycin product (1.55 Å resolution) and in complex with the bacillithiol-fosfomycin product (1.77 Å resolution) coordinated to a Mn 2+ metal in the active site have been determined. The L-Cys moiety of either product is located in the solvent channel, where the thiol has added to the backside of fosfomycin C1 located at the end of the channel. Concomitant kinetic analyses of FosB Bc indicated that the enzyme has a preference for BSH over L-Cys when activated by Mn 2+ and is inhibited by Zn
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, indicate that the antibiotic coordinates to the active site metal center in an orientation similar to that found in the structurally homologous manganese-dependent fosfomycin resistance enzyme, FosA. Surface analysis of the FosB Bc structures show a well-defined binding pocket and an access channel to C1 of fosfomycin, the carbon to which nucleophilic addition of the thiol occurs. The pocket and access channel are appropriate in size and shape to accommodate L-Cys or BSH. Further investigation of the structures revealed that the fosfomycin molecule, anchored by the metal, is surrounded by a cage of amino acids that hold the antibiotic in an orientation such that C1 is centered at the end of the solvent channel, positioning the compound for direct nucleophilic attack by the thiol substrate. In addition, the structures of FosB Bc in complex with the L-Cys-fosfomycin product (1.55 Å resolution) and in complex with the bacillithiol-fosfomycin product (1.77 Å resolution) coordinated to a Mn 2+ metal in the active site have been determined. The L-Cys moiety of either product is located in the solvent channel, where the thiol has added to the backside of fosfomycin C1 located at the end of the channel. Concomitant kinetic analyses of FosB Bc indicated that the enzyme has a preference for BSH over L-Cys when activated by Mn 2+ and is inhibited by Zn
. The fact that Zn 2+ is an inhibitor of FosB Bc was used to obtain a ternary complex structure of the enzyme with both fosfomycin and L-Cys bound.
M icrobial resistance to antibiotic compounds was recognized almost immediately after their introduction in the 1940s. The growing threat has culminated in the emergence of multiple-drug-resistant organisms that are invulnerable to treatment with several antimicrobial agents. Although the exact mechanism of antibiotic resistance can vary, antibiotic-modifying enzymes represent the most common mode of microbial survival and are, therefore, obvious targets for the development of new therapeutic agents. Combination therapies of administering antibiotics with additional enzyme inhibitors have already proven successful with the use of β-lactamase inhibitors to combat β-lactam resistant bacterial strains.
Fosfomycin, or (1R,2S)-epoxypropylphosphonic acid, is a safe, broad-spectrum antibiotic produced by various bacteria of the genus Streptomyces. It was initially characterized in 1969 1 and is used in the United States under the trade name Monurol. It is effective against both Gram-positive and Gram-negative bacteria owing to its ability to inhibit cell wall biosynthesis by inactivating the enzyme, UDP-N-acetylglucosamine-3-enolpyruvyltransferase or MurA. MurA catalyzes the initial step of peptidoglycan biosynthesis by transferring the enolpyruvyl moiety of phosphoenolpyruvate to the 3′-hydroxyl group of UDP-N-acetylglucosamine. The lactoyl moiety of the resulting UDP-N-acetylmuramic acid eventually provides a linker that bridges the glycan and peptide portions of peptidoglycan, a historically important target for antimicrobial agents. Fosfomycin is a phosphoenolpyruvate analog that covalently attaches to an active site cysteine of MurA, irreversibly inhibiting the enzyme and shutting down peptidoglycan biosynthesis. 2−4 Fosfomycin is most often prescribed for the treatment of urinary tract and gastrointestinal infections. 5, 6 It has few human side effects and is eliminated from the body in its unmetabolized, active form. Therefore, it can be administered in a single 3 g dose that potentially circumvents two microbial resistance mechanisms, specifically, decreased cell permeability and active efflux pumping. 7 A significant disadvantage to its effectiveness, however, has been the emergence of enzymes that modify the antibiotic.
There are currently three distinct classes of fosfomycin resistance enzymes ( Figure 1 ). FosA enzymes are Mn 2+ -and K + -dependent glutathione-S-transferases that catalyze nucleophilic addition of glutathione (GSH) to C1 of fosfomycin, opening the epoxide ring of the antibiotic and resulting in a modified compound with no bactericidal properties. 8−11 Genes encoding FosA have been identified in several Gram-negative bacterial species including the opportunistic human pathogen Pseudomonas aeruginosa. 12 FosX enzymes are Mn 2+ -dependent hydrolases that catalyze the hydration of fosfomycin at C1 forming a vicinal diol and inactivating the antibiotic. 13, 14 FosB enzymes were discovered in Gram-positive organisms such as Staphylococcus aureus and Bacillis subtilis 15, 16 and catalyze the M 2+ -dependent addition of L-cysteine (L-Cys) or bacillithiol (BSH) to C1 of fosfomycin. 17 The L-Cys transferase activity of FosB from B. subtilis is poor (k cat /K M thiol ∼180 M −1 s −1 ) 15 when compared to the GSH transferase activity of FosA from P. aeruginosa (k cat /K M thiol ∼1.7 × 10 5 M −1 s −1 ) 15 and is not sufficient to confer robust resistance to fosfomycin. However, recent kinetic analyses of the FosB enzymes from multiple organisms, conducted in the Armstrong laboratory, have indicated that bacillithiol is the preferred thiol substrate of the FosB enzymes in vitro.
17
GSH is not produced by Gram-positive bacteria, which explains why the FosB enzymes have not evolved to be glutathione transferases. Instead, BSH is a abundant low molecular weight thiol found in nearly equal concentrations as L-Cys. BSH ( Figure 2 ) was first isolated and identified in 2009 from S. aureus and Deinococcus radiodurans. 18 Similar to the function of mycothiol in Mycobacterium, BSH serves as a substitute for glutathione in Gram-positive bacteria like S. aureus, 19, 20 and BSH knockout/null cells exhibit a significant increase in their sensitivity to fosfomycin. 20 FosB catalyzes the addition of the cysteinyl-moiety of BSH to C1 of fosfomycin similar to FosA addition of GSH. These results have led to the FosB enzymes being classified as bacillithiol-S-transferases. The recent discovery of BSH, along with preliminary activity data, has motivated an effort to characterize the role of BSH in antimicrobial resistance of Gram-positive organisms.
Herein Bc was expressed and purified for activity assays as previously described by our lab. 17 FosB Bc (0.25 μM) was equilibrated for 5 min with either 1 mM MgCl 2 , 10 μM NiCl 2 , or 10 μM MnCl 2 and 4 mM fosfomycin in 20 mM HEPES (pH 7.0). The reaction was initiated by the addition of 2 mM BSH or L-Cys, transferred to an NMR tube, and allowed to react at 298 K. At various time points, a 31 P with 1 H decoupling NMR spectrum was collected using Bruker DRX-500 MHz NMR. Analysis of the data was completed according to the method previously described by our lab. The cells were plated on LB agar containing 100 ug/mL of ampicillin and incubated at 37°C for approximately 16 h. Single colonies were isolated from the LB-agar plates and used to inoculate 2 mL of LB (Gibco) starter cultures (3 cultures for a total of 6 mL) containing 80 ug/mL of ampicillin. After approximately 8 h of incubation at 37°C with shaking, 1 mL of starter growth was used to inoculate 1 L of Terrific Broth containing 80 ug/mL of ampicillin (6 L total) . The 1 L cultures were grown at 37°C with shaking for approximately 12 h (or until the OD 600 reached ∼1) and then induced with 0.5 mM IPTG. Upon induction with IPTG, the temperature was reduced to 25°C, and the cells were allowed to grow for an additional 4 to 5 h. The cells were harvested by centrifugation at 5000g for 15 min.
The E. coli cell pellet was resuspended in 2 mL of lysis buffer (20 mM Tris HCL, pH 7.5) per gram of cell pellet. Lysozyme was added to the slurry at 1 mg/mL, and the mixture was stirred at 4°C for 1 h. After 1 h of stirring, 5 mg of DNase and RNase were added, and the slurry was stirred at 4°C for another hour. The slurry was sonicated to ensure complete lysing of cells, and the lysate was cleared by centrifugation at 35 000g for 30 min.
An ammonium sulfate precipitation was performed on the cleared lysate solution prior to any column purification. Fractions were precipitated at 5, 20, 40, 60, 80, and 95% ammonium sulfate. The fractions were analyzed by SDS-PAGE, and fractions containing the highest ratio of FosB to other proteins were combined for further purification. The protein was dialyzed overnight in 20 mM HEPES buffer (pH 7.0) to remove any residual lysis buffer or salt that could interfere with ion-exchange chromatography.
The collected fractions were pooled, concentrated, and loaded onto a GE Healthcare HiPrep DEAE FF 16/10 column, equilibrated with 20 mM HEPES (pH 7.0) using an Amersham Pharmacia Biotech AKTAdesign FPLC (equipped with a 50 mL super loop). With an estimated pI of 5.22, FosB
Bc adheres to the DEAE material, and a purple hue can be seen on the column. The protein was eluted from the column at 2 mL/min using a gradient of 0−30% NaCl in the same buffer. Fractions were analyzed for purity by SDS-PAGE. The most pure fractions were collected, combined, and dialyzed overnight into 10 mM sodium phosphate (pH 7.0).
The protein, in 10 mM sodium phosphate buffer (pH 7.0), was subsequently loaded onto a 2.5 × 15 cm hydroxyapatite column (BioRad, Hercules, CA). FosB
Bc adheres to the hydroxyapatite material. The protein was eluted from the column with an increasing concentration of phosphate. The protein eluted between 100 and 400 mM phosphate according to fractions analyzed by SDS-PAGE.
Finally, the protein was dialyzed into 50 mM sodium phosphate buffer (pH 7.5) containing 150 mM NaCl and 5 mM DTT. The protein was concentrated to approximately 1 mL with an Amicon 10K molecular weight cutoff membrane and loaded onto a GE Healthcare 26/60 Sephacryl column at 1 mL/min using an Amersham Pharmacia Biotech FPLC. Fractions were collected from the column at 0. 5 
For FosB
Bc with Mn 2+ and 3, crystals were obtained after mixing equal volumes (3 uL) of the protein solution (13 mg/ mL in 20 mM HEPES buffer (pH 7.5), 8 mM fosfomycin, 8 mM BSH, and 5 mM DTT; incubated for ∼1 h on ice) and reservoir solution (0.1 M magnesium formate and 14% (w/v) poly(ethylene glycol) 3350). All crystals were cryoprotected in the mother solution and 15% glycerol prior to freezing in liquid nitrogen and data collection.
Data Collection and Refinement. Screening for the diffraction of crystals was performed at the Biomolecular Crystallography Facility in the Vanderbilt University Center for Structural Biology using a Bruker-Nonius Microstar rotating anode X-ray generator equipped with a Proteum PT135 CCD area detector mounted on an X8 kappa goniometer with Montel confocal multilayer optics. Crystals were maintained at 100 K using a Bruker KryoFlex cryostat.
Diffraction data for all crystals were collected at 100 K on the LS-CAT 21-ID beamline at the APS synchrotron facility. The collected diffraction data sets were processed with HKL2000. 21 Phasing of diffraction data was done either by molecular replacement using PHASER 22 or by SAD phasing using SHELXD/E. 23 For SAD phasing, the presence of the anomalous scatterer was confirmed and the peak wavelength determined by X-ray fluorescence. Two anomalous scatterers were located in the asymmetric unit corresponding to two active sites in the enzyme. In the case of SAD phasing, initial models were constructed using ARPwARP. 24 For molecular replacement, the first model output and refined from ARPwARP was used as the initial search model. All crystals belong to the P2 1 2 1 2 1 space group and contain 276 amino acids in the asymmetric unit, which represents the complete FosB enzyme. Manual model building for each structure was performed using Coot model building software. 25 Water molecules were placed with the Coot routine, Find Waters. The final models were obtained by iterative cycles of model building in Coot and structure refinement using Refmac5 26 in the CCP4 suite of programs (Collaborative Computational Project, 1994). All protein figures were prepared with Chimera. 27 Data collection and refinement statistics are given in Table 1 .
X-ray Fluorescence Spectroscopy. All X-ray fluorescence spectra of the crystals were collected at 100 K on the LS-CAT (Figure 3a) . The concentration of Mg 2+ was originally selected to be much greater than K act (∼200 uM) for the homologous FosB enzyme from B. subtilis. 15 The results Figure S1 ). The presence of a high concentration of zinc was confirmed by an X-ray fluorescence scan of the crystal prior to collection of diffraction data ( Figure S2) . Subsequently, the diffraction data were collected at a wavelength of 1.28 Å, the K α absorption edge of Zn 2+ , and Zn 2+ was used to model the density. ·sulfate structure (PDB 4JH1), the initial phases were determined using Zn 2+ SAD phasing at 1.28 Å wavelength. The anomalous density map, contoured at 5σ, is displayed in Figure S3 and outlines the location of the modeled Zn 2+ metal ions. and fosfomycin bound in the active site was obtained to 1.89 Å resolution ( Figure S4 ). The initial phases were determined using Ni 2+ SAD phasing at 1.48 Å wavelength, the K α absorption edge of Ni
2+
. An X-ray fluorescence scan of the crystal prior to diffraction data collection indicated the presence of Ni 2+ ( Figure S5 ). The anomalous density map, modeled using Ni
, is displayed in Figure S4 and marks the location of the Ni 2+ metal ions.
FosB
Bc with Cobalt and Fosfomycin (SAD Phasing). (PDB 4JH5) The crystal structure of FosB Bc with Co 2+ and fosfomycin bound in the active site was refined to 1.77 Å resolution ( Figure S6 ). The initial phases were determined using Co 2+ SAD phasing at 1.61 Å wavelength. Again, an X-ray fluorescence scan of the crystal prior to diffraction data collection indicated the presence of Co 2+ ( Figure S7 ), and the diffraction data were collected at the K α absorption edge of (Figures 4 and 5a) . The structure was solved by molecular replacement using the initial structure of FosB
Bc ·Zn 2+ where the Zn 2+ was removed from the coordinate file before the phasing process. A SAD experimental data set was not collected for this crystal because of the 1.89 Å K α absorption edge of Mn that yielded excellent SAD phasing data, it is safe to assume that the metal-ion density is that of Mn 2+ .
Bc with Manganese and L-Cysteine-Fosfomycin Product (Molecular Replacement). (PDB 4JH7) The FosB Bc · Mn 2+ ·2 product complex was obtained to 1.55 Å resolution (Figure 5b ). The structure was solved by molecular replacement. The presence of Mn 2+ in the crystal was verified by X-ray fluorescence. The B factors for each of the metal sites in the crystal indicate Mn 2+ ions are a good fit for the observed electron density, as the B factor for Mn 2+ in one site is 8.1 Å 2 , and the coordinating amino acids have average B factors of 7.9, 7.1, and 6.7 Å 2 for His7, His66, and Glu115, respectively. A library file in CIF format for (1R,2S)-1-(S-L-cysteinyl)-2-hydroxypropylphosphonate was created using the online PRODRG Server 28 and inserted into the model during the final refinement. carbon of fosfomycin appears to be more substrate-like in character than that of the product complex (compare panel c to panel a of Figure 5 ). Moreover, there is strong electron density above C1 that is almost certainly that of sulfur. The ambiguity in the rest of the density for the cysteine likely arises from a combination of occupancy and multiple conformations in the solvent channel.
FosB Bc with Mn 2+ and Bacillithiol-Fosfomycin Product Complex (Molecular Replacement). (PDB 4JH9) The FosB
Bc · Mn 2+ ·3 product complex was obtained to 1.55 Å resolution. The structure was solved by molecular replacement. The same (1R,2S)-1-(S-L-cysteinyl)-2-hydroxypropylphosphonate product was used to model the observed density in the active site because the glucosamine-malate domain of BSH was not observed ( Figure S9 ).
Structural Characterization of FosB Bc . As anticipated, the overall structure of FosB Bc (Figures 4, S3, S4 , and S6) reveals that the enzyme is a homodimer and belongs to the vicinal oxygen chelate (VOC) superfamily of enzymes similar to FosA, FosX, 12, 13, 29 and the recently deposited FosB structure from Bacillus anthracis (FosB Ba , PDB 4IR0). The VOC superfamily of metalloenzymes is characterized by a 3D domain-swapped arrangement of tandem βαβββ motifs in which both subunits of the homodimer participate in coordination of each metal ion and formation of the U-shaped active sites in the enzyme. 30 All of the reported structures maintain the overall arrangement with little variation. The overall rmsd for all atoms of the nine reported FosB
Bc structures is 0.32 Å, calculated with Chimera. 27 Like the FosA and FosX enzymes, two histidines and a glutamic acid in FosB Bc serve as the protein ligands that coordinate the metal ion. Specifically for FosB Bc , they are His7, His66, and Glu115. In the FosB Bc ·Zn
2+
·sulfate structure (PDB 4JH2), the Zn 2+ adopts a tetrahedral coordination geometry, with a sulfate oxygen occupying the fourth coordinate site of the inner-coordination sphere of the metal. The 2F o −F c difference density calculated prior to the addition of sulfate to the coordinate file clearly establishes the presence of the sulfate ion coordinated to Zn 2+ ( Figure S1 ). The ligand−metal distances are 2.02, 1.99, and 2.01 Å for His7, His66, and Glu115, respectively, with a metal−sulfate oxygen distance of 1.90 Å.
Structure (Figure 5b ). In the structure, the epoxide ring of fosfomycin has been opened via nucleophilic addition of L-Cys to C1 of fosfomycin. The C1 of fosfomycin is sp 3 hybridized, and strong electron density is observed for the sulfur. The L-Cys-fosfomycin product molecule was constructed in PRODRG 28 according to the stereochemistry originally reported by Bernat et al, which was biosynthesized using the FosA enzyme. 31 Thus, the resulting 2 , and the density for C1 of 1 is sp 3 hybridized following nucleophilic attack by the L-Cys thiol. The electron density in panel c shows 1 coordinated to Zn 2+ , with the density for the C1 carbon of 1 more substrate-like in geometry than that of panel b, indicating no product formation. The strong electron density above C1 likely belongs to sulfur. The ambiguity in the rest of the density for the L-Cys is probably due to a combination of occupancy and multiple conformations in the crystal.
product can be correctly identified as (1R,2S)-1-(S-L-cysteinyl)-2-hydroxypropylphosphonate, the same product as that reported for FosA. 31 Inversion of configuration at C1 indicates that the reaction proceeds via direct S N 2 addition of the thiol to the oxirane carbon.
The ligand−metal distances in the FosB Bc ·Mn
·2 structure are 2.16, 2.16, and 2.07 Å for His7, His66, and Glu115, respectively. The metal to phosphonate oxygen distance is 2.02 Å, with a metal to oxirane oxygen distance of 2.36 Å.
FosB Bc with Zinc and Ternary Complex (Molecular Replacement). The crystals of FosB
Bc grown in the presence of Zn
2+
, fosfomycin, and L-Cys yielded electron density that most closely resembles the fosfomycin and L-Cys cosubstrates (Figure 5c ). The density for the C1 carbon of fosfomycin is more substrate-like in geometry than that of the product complex (Figure 5b ). In addition, the strong electron density above C1 has a peak of 17.30σ, too intense for even the most well-ordered water molecules. Moreover, when refined with LCys, the sulfur atom has a B factor of 27.1 Å 2 averaged over the two sites. This value compares quite well with the overall B factor for the structure of 19.7 Å 2 . Furthermore, the oxygen of Tyr39 is 3.25 Å from the sulfur, and the location of the sulfur superimposes that of the thioether of 2 in the FosB Bc ·Mn 2+ ·2 structure. Finally, the distance between C1 of 1 and the sulfur is 2.79 Å. This distance is significantly shorter than the theoretical van der Waals interaction of 3.50 Å yet much longer than a typical carbon−sulfur single bond (1.83 Å) and likely represents the location of the sulfur when it is poised for nucleophilic attack of the antibiotic. The ambiguity in the rest of the density for the L-Cys probably arises from a combination of occupancy and multiple conformations throughout the crystal. Nevertheless, there is enough density to correctly establish the location of the L-Cys sulfur.
This structure is not intended to serve as evidence for the location of the L-Cys binding site. That location is made crystal clear by the FosB Bc ·Mn 2+ ·2 structure described above. Rather, this structure is presented as a ternary structure with both substrates in the active site, which was an anticipated result given that Zn 2+ is a potent inhibitor of enzymatic activity for FosB Bc (Figure 3 ). The most interesting aspect of this structure is the position of Asn50. The electron density for Asn50 in this structure has the residue oriented perpendicular to that of all of the other structures, an orientation that positions the O δ of Asn50 4.13 Å from C1 of fosfomycin and N δ of Asn50 4.20 Å from the sulfur of L-Cys. Superposition of the Zn 2+ ternary-complex structure and the Mn 2+ product-complex structure shows that, whereas the positions of all other amino acids stay the same, Chi2 of Asn50 in the ternary complex is rotated approximately 90°r elative to the product complex ( Figure 6 ). This structure of FosB Bc is the only structure that shows significant displacement of any amino acid. In the structure, the epoxide ring of fosfomycin has been opened via nucleophilic addition of BSH. However, electron density for the complete 3 is not observed. Rather, the electron density more closely resembles that of 2 even though L-Cys was never introduced into the crystallization conditions. It is unclear if the L-Cys moiety has somehow been removed from the glucosamine-malate portion of BSH or if the glucosaminemalate moiety is simply not homogeneous in the crystal. Either scenario would give rise to the observed density that resembles 2 only. However, the second scenario is more plausible. First, Roberts et al. reported a purification procedure for 3 that involves heating for 10 min at 85°C followed by derivatization with AQC (6-aminoquinolyl-N-hydroxysuccinimidyl carbamate) at pH 8.8 and then adjustment to pH 5.5 for HPLC analysis, 32 thereby establishing the inherent stability of 3 over a broad temperature and pH range. Second, Roberts et al. were unable to dock a BSH molecule into the crystal structure of FosB from B. anthracis (FosB Ba , PDB 4IR0) and attributed the failure to a possible conformational change that may take place in the enzyme when BSH binds. 32 Protein flexibility is critical for proper enzymatic function, and the rigidity of the crystal may prevent proper seating of the BSH molecule to the enzyme. Finally, the unit cell dimensions for this crystal (PDB 4JH9) are different than the others reported. The average unit cell dimensions for the other eight structures are 64.37 ± 0.07, ·1·L-Cys ternary structure (PDB 4JH8). Although the positions of all other amino acids stay the same, Asn50 in the ternary complex is rotated approximately 90°relative to the product complex. Rotation of Asn50 about the C β −C γ bond is the only significant difference observed in the reported structures of FosB
Bc . The conserved residues, Tyr39 and Asn50, likely work in a concerted manner to ionize and stabilize the approaching thiolate during nucleophilic attack of the antibiotic.
68.36 ± 0.21, and 69.96 ± 0.26 Å, whereas the unit cell dimensions for the crystal with 3 are 56.48, 64.48, and 83.91 Å (Table 1) , indicating a significant difference in crystal packing. Given the stability of 3 and the fact that L-Cys was never introduced into the crystallization conditions, it is reasonable to assume that 3 is present and simply not observed in the electron density. Thus, what is observed in the structure is the phosphonate end of the product molecule tethered to the Mn 2+ metal within the enzyme, whereas the remainder of the molecule is solvent exposed and disordered on the surface of the enzyme within the crystal ( Figure S9 ).
■ DISCUSSION

Our initial crystals of FosB
Bc (PDBs 4JH1, 4JH2, and 4JH3) contained Zn 2+ in the active site similar to the structure of FosB from B. anthracis (PDB 4IR0). The metal was confirmed via Xray fluorescence and SAD phasing from the K α edge of Zn 2+ . These crystals were grown from preparations of FosB Bc purified from cells grown in terrific broth media without further manipulation to remove or add specific metals. Therefore, Zn 2+ was the divalent metal "selected" by the enzyme from the growth conditions. Given that both our initial crystals and the crystal of FosB Ba had Zn 2+ in the active, we tested the activation of FosB
Bc for both L-Cys and BSH transferase activity using the enzyme prepared specifically with Zn 2+ . (Figure 3a, 
b). This divalent metal activation of FosB
Bc is in excellent agreement with the homologous classes of fosfomycin resistance enzymes, FosA and FosX, where both are most activated by Mn 2+ and show only very minimal activity with Zn 2+ in the presence of their respective nucleophiles. 10, 13 The preference of FosB Bc for BSH over L-Cys suggests that the glucosamine-malate domain of the BSH molecule is important for substrate recognition. Substitution of the malate motif of BSH with either an O-methyl or O-benzyl aglycone group results in a 10-and 18-fold increase in K m , respectively, of the substrate for FosB from S. aureus. 32 Thus, the thermodynamic driving force of nucleophilic addition is likely interaction of the glucosamine-malate domain with the surface of the enzyme.
Surface analysis of the FosB Bc structures revealed a welldefined pocket and access channel to C1 of fosfomycin, the carbon to which nucleophilic addition of the thiol occurs. The pocket and access channel are appropriate in size and shape to accommodate L-Cys or BSH. Fosfomycin is positioned in the enzyme such that the backside of the oxirane carbon to be attacked is directly centered at the end of the solvent access channel (Figure 7) .
The role of the binding pocket and access channel are made clear by either the FosB Bc ·Mn 2+ ·2 product complex (PDB 4JH7) or the FosB Bc ·Mn
2+
·3 product complex (PDB 4JH9). In either structure, nucleophilic addition of the thiolate to C1 of 1 has occurred at the end of the channel (Figure 8 , PDB 4JH7 shown). The opening of the binding pocket from the access channel begins at the C α end of the cysteinyl moiety, where the remainder of the bacillithiol domain would be connected through the secondary amine of 3. Unfortunately, in PDB 4JH9, the complete 3 was not observed seated in the binding pocket of the crystal for reasons described vide supra.
The fosfomycin molecule, coordinated to the metal, is surrounded by a cage of amino acids positioned appropriately to anchor the antibiotic in the aforementioned orientation ( Figure 9) . Inspection of the cage reveals it has both polar and nonpolar ends to accommodate fosfomycin. The polar phosphonate group of the antibiotic is coordinated to the metal through one of the phosphonate oxygens and hydrogen bonded to Arg94, Arg124, Tyr64, and Tyr105 through the other two. The triangular cage structure around the phosphonate end is maintained by a salt bridge from Arg94 to Asp100 and hydrogen bonds from Arg124 to Tyr39 and Asp100. On the opposite end, the oxirane oxygen is coordinated to the metal such that the methyl group of fosfomycin is held adjacent to Trp46 and C2 of fosfomycin is pointed directly at Ala48. The amino acids that construct the fosmomycin cage structure and form hydrogen bonds to the antibiotic are conserved throughout all of the FosB enzymes ( Figure S10, green) .
The conserved residues, Arg94 and Asp100, that form the salt bridge of the loop region in FosB that encloses the phosphonate group of fosfomycin are not found in FosA (PA1129). Rather, in FosA (PA1129) the region (approximately aa 90−100) is composed of amino acids that form the potassium binding loop. K + is required for the optimum activation of FosA 11 but not for FosB. Tyr39 is conserved in both the FosA and FosB enzymes. From the energy-minimized docking results, Tyr39 of FosA was reported to be in a favorable position to ionize GSH, being 3.45 Å away from the docked substrate thiol. 33 In both the FosB Bc · Zn 2+ ternary complex (PDB 4JH8) and the FosB Bc ·Mn 2+ ·2 complex (PDB 4JH7), Tyr39 is located approximately 3.31 Å from the L-Cys sulfur, which is consistent with the docking results for GSH to FosA. Mutation of Tyr39 to phenylalanine in FosA (PA1129) resulted in a 13-fold reduction in enzymatic turnover and a 50-fold decrease in catalytic efficiency for the thiol substrate, k cat /K M GSH . 33 Thus, the function of Tyr39, in either FosA or FosB, is likely to abstract a proton from and activate the incoming thiol during the reaction. Hydrogen bonding of Tyr39 to Arg124 (Figure 9) (Figure S10, red) . FosB Ss has a threonine at position 9, In the final refinement, R work = 13.33% and R free = 18.64%. The difference electron density shown for 2 is the 2F o −F c map calculated before the addition of 2 to the coordinate file. It is contoured at 3σ and emphasizes the quality of the data. The C1 of fosfomycin is clearly sp 3 hybridized, and strong electron density is observed for the sulfur. Figure 9 . Fosfomycin molecule surrounded by a cage of amino acids. The cage has both a polar and nonpolar end to accommodate the antibiotic. The polar phosphonate group is coordinated to the metal through one of the phosphonate oxygens and is hydrogen bonded to Arg94, Arg124, Tyr64, and Tyr105 through the other two. On the opposite end, the oxirane oxygen is coordinated to the metal, and the hydrophobic methyl group of fosfomycin is held adjacent to Trp46. The amino acids that construct the fosmomycin cage are conserved throughout all of the FosB enzymes ( Figure S10, green) . This figure was made with PDB 4JH3. the same as FosA (PA1129). 12 In FosA (PA1129), the Thr9 residue is proposed to activate the oxirane oxygen of fosfomycin. Similarly for FosB Bc , FosB Sa , and FosB
Ba
, Cys9 has been proposed to active the oxirane oxygen. However, in FosB Bs , there is no analogous amino acid at this position that could serve to activate the fosfomycin molecule. This lack in conservation at amino acid position 9 of the FosB enzymes suggests an alternative mode of activation of the epoxide oxygen of fosfomycin rather than simply protonation by either a hydroxyl or sulfhydryl side chain as previously suggested. 12 
Superposition of the FosB
Bc ·Mn 2+ ·1 (PDB 4JH6) and FosB
Bc ·Mn 2+ ·2 (PDB 4JH7) product structures provides some insight into the metal-ion assisted activation of the antibiotic. When the L-Cys thiol adds to C1 of fosfomycin and the epoxide ring opens, the Mn 2+ metal displaces from the three coordinating amino acids such that the overall coordination geometry of Mn 2+ changes (Figures 10 and S11 and Table 2 ). If the Z axis is defined along E115O ε −Mn 2+ −Fosfomycin-O (oxirane) (Figures 11 and S11) , then there is a distorted trigonal bipyramidal geometry about the Mn 2+ center similar to that observed in FosA. When the product is formed, the equatorial distances expand, and the metal−oxygen (oxirane) bond shortens, effectively creating a more symmetric trigonal bipyramidal geometry around Mn 2+ and relieving strain on both the atomic orbitals of the metal and the epoxide ring of the antibiotic. The observed changes in metal−ligand bond distances are on the order of approximately 0.1 Å. These observable deviations are justified given that the estimated overall coordinate errors from maximum likelihood refinement are 0.03 and 0.04 Å for the FosB 
·1 (PDB 4JH6) and FosB
Bc ·Mn 2+ ·2 (PDB 4JH7) structures. When the L-Cys thiol adds to C1 of fosfomycin and the epoxide ring opens, the Mn 2+ metal displaces from the three coordinating amino acids such that the overall coordination geometry of Mn 2+ changes. Specifically, the equatorial distances expand, and the metal−oxygen (oxirane) bond shortens, effectively creating a more symmetric trigonal bipyramidal geometry around Mn 2+ and relieving strain on both the atomic orbitals of the metal and the epoxide ring of the antibiotic (Table 2) . , significantly increasing the polarity of the C1−O (oxirane) bond and resulting in greater partial positive charge (δ + ) on C1. In addition, the electron-withdrawing nature of the phosphonate group will further enhance δ + on C1 through polarization of the C1−P bond. Arrows denote electron charge redistribution away from C1 to both the phosphonate and the epoxide oxygen. This primes the antibiotic for nucleophilic attack by the thiol substrate. This figure was made with PDB 4JH6. C1−O (oxirane) bond of fosfomycin, resulting in greater partial positive charge (δ + ) on C1. In addition, the electronwithdrawing nature of the phosphonate group will further enhance δ + on C1 through polarization of the C1−P bond. Electron charge redistribution away from C1 to both the phosphonate and the epoxide oxygen significantly increases the δ + on C1 and primes the antibiotic for nucleophilic attack by the thiolate substrate (Figure 11 ).
In the Mn 2+ ·FosB Bc ·2 structure, O δ of Asn50 is 3.80 Å from C1 of 2 and N δ of Asn50 3.61 Å from the thioether of 2 averaged over the two active sites. These distances are on the edge of van der Waals interactions for the nuclei. Asn50 is also conserved throughout the FosB enzymes ( Figure S10, red) but not in FosA. In FosA (PA1129), the position is occupied by a serine residue (Ser50) that has been implicated in GSH binding. 33 Bc ·2 product structures clearly shows that Asn50 adopts two conformations, one perpendicular (ternary complex) and one nearly parallel (product complex) to the C1−S bond of the L-Cys-fosfomycin product (Figure 6 ), the same orientation as it is observed in the other seven structures whether fosfomycin is present or not. The latter orientation is maintained by a hydrogen bond between O δ of Asn50 and the thiol of the adjacent Cys9 in the active site. Rotation of Asn50 about the C β −C γ bond is the only significant variation observed in the reported structures of Bc , Tyr39 and Asn50 work in a concerted manner to ionize and stabilize the approaching thiolate during the reaction ( Figure 6 ).
The same rationale for why this family of fosfomycin resistance enzymes is activated by Mn 2+ can be used to explain why the enzymes, including FosA and FosX, are the least activated or even inhibited by Zn 2+ . Zn 2+ is the softest acid of the metals tested and will therefore form the weakest Lewis acid/base complex with the lone pair electrons of the oxirane oxygen. Furthermore, given that Zn 2+ is a d 10 metal species, the d z 2 orbital is full and therefore unable to accept electron donation from the lone pair, resulting in a decreased δ + on C1 of fosfomycin. Therefore, even though Zn 2+ is the strongest Lewis acid of the metals tested, it will form the weakest Lewis acid/base complex with the oxirane lone pair of fosfomycin because of the energetically unfavorable soft−hard combination.
■ CONCLUSIONS
The mechanism of FosB
Bc is acid-catalyzed nucleophilic epoxide ring-opening, where Mn 2+ serves as the Lewis acid. Fosfomycin is activated by the formation of a strong Lewis acid/base complex with Mn 2+ . The resultant complex serves to enhance δ + on C1 through polarization of the C1−O (oxirane) bond in addition to the already polarized C1−P bond of the antibiotic. Tyr39 facilitates ionization of the incoming thiol, while Asn50 stabilizes both the δ + on C1 of fosfomycin and S − of the incoming nucleophile. Inversion of configuration at C1 indicates that the reaction proceeds via direct S N 2 addition of the thiol to the oxirane carbon, forming the same (1R,2S)-1-(S-L-cysteinyl)-2-hydroxypropylphosphonate (or (1R,2S)-1-(S-bacillithiolyl)-2-hydroxypropylphosphonate) product as that formed by FosA. 31 Antibiotic modifying enzymes represent a common mode of microbial resistance and are, therefore, obvious targets for the development of new therapeutic agents. Characterizing the interaction between resistance enzymes and their cosubstrates is a critical step toward the discovery of lead compounds to combat antimicrobial resistant bacteria. The L-Cys-fosfomycin product structure confirms the role of the solvent channel in FosB Bc and represents a major contribution in understanding the mechanism of the enzyme. However, given that BSH is the preferred substrate of FosB over L-Cys, part of the thermodynamic driving force of the reaction must be the interaction of the enzyme with the glucosamine-malate portion of BSH. To target FosB therapeutically, this interaction must still be characterized.
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Active site residues that define the metal-ion and sulfate binding sites from the X-ray crystal structure of the FosB protein from Bacillus cereus in complex with Zn 2+ and sulfate at 1.55 Å resolution. Active site residues that define the metal-ion and fosfomycin binding sites from the second crystal structure of 
